CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.
How this was made
The 30-second read
Why it matters
The Phase 1 data presentation is the first public glimpse of zugo‑cel, a novel allogeneic CAR‑T targeting CD19 for autoimmune indications, which could validate the platform and attract partnership or funding.
Market read
Investors will watch the data for clues on efficacy, safety, and commercial potential of a new CAR‑T approach, which could affect CRSP valuation and peer biotech stocks.
What to watch
Regulatory timeline and manufacturing scalability for allogeneic CAR‑T may temper enthusiasm.
Background
CRISPR Therapeutics is a leading CRISPR‑based gene‑editing company with an approved therapy (CASGEVY) and a pipeline spanning hemoglobinopathies, cardiovascular, autoimmune, oncology, and rare diseases.
Ticker impact
CRISPR Therapeutics announced it will present Phase 1 data on its allogeneic CAR‑T therapy zugo‑cel at the ACR Convergence on Nov 8, 2026 – first public disclosure of this trial data.
potential upward pressure if data are positive; downside risk if safety concerns emerge
Phase‑1 data are material for a biotech; investors typically react strongly to early‑stage results.
Market effects
May influence sentiment toward the broader gene‑editing and CAR‑T sector.
Primarily U.S. biotech investors; limited broader market effect.
Limited to investors tracking CRISPR and gene‑editing pipelines.
Counterpoint
If the data are modest, the stock could underperform peers expecting breakthrough results.
Key entities
- CompanyCRISPR Therapeutics
Nasdaq‑listed biotech developing CRISPR‑based therapies.
- OrganizationAmerican College of Rheumatology (ACR)
Venue for the poster presentation of the trial data.
